Investigator

Sander Dumont

Gynaecologist · AZ Groeninge, Department of Gynaecology and Obstetrics

About

SDSander Dumont
Papers(1)
Predicting resectable…
Collaborators(7)
Thaïs BaertToon Van GorpValérie BroeckhovenVincent VandecaveyeEls Van NieuwenhuysenFrédéric AmantRaphaëla Carmen Dresen
Institutions(3)
Ku LeuvenEuropean UnionKU Leuven

Papers

Predicting resectable disease in relapsed epithelial ovarian cancer by using whole-body diffusion-weighted MRI

To determine the diagnostic value of whole-body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) to predict resectable disease at the time of secondary cytoreductive surgery for relapsed epithelial ovarian cancer with a platinum-free interval of at least 6 months. A retrospective cohort study between January 2012 and December 2021 in a tertiary referral hospital. Inclusion criteria were: (a) first recurrence of epithelial ovarian cancer; (b) platinum-free interval of ≥6 months; (c) intent to perform secondary cytoreductive surgery with complete macroscopic resection; and (d) WB-DWI/MRI was performed.Diagnostic tests of WB-DWI/MRI for predicting complete resection during secondary cytoreductive surgery are calculated as well as the progression-free and overall survival of the patients with a WB-DWI/MRI scan that showed resectable disease or not. In total, 238 patients could be identified, of whom 123 (51.7%) underwent secondary cytoreductive surgery. WB-DWI/MRI predicted resectable disease with a sensitivity of 93.6% (95% confidence interval [CI] 87.3% to 96.9%), specificity of 93.0% (95% CI 87.3% to 96.3%), and an accuracy of 93.3% (95% CI 89.3% to 96.1%). The positive predictive value was 91.9% (95% CI 85.3% to 95.7%).Prediction of resectable disease by WB-DWI/MRI correlated with improved progression-free survival (median 19 months vs 9 months; hazard ratio [HR] for progression 0.36; 95% CI 0.26 to 0.50) and overall survival (median 75 months vs 28 months; HR for death 0.33; 95% CI 0.23 to 0.47). WB-DWI/MRI accurately predicts resectable disease in patients with a platinum-free interval of ≥6 months at the time of secondary cytoreductive surgery and could be of complementary value to the currently used models.

19Works
1Papers
7Collaborators
Carcinoma, Ovarian EpithelialOvarian NeoplasmsDelayed DiagnosisIatrogenic DiseaseDisease Models, AnimalDisease Susceptibility

Positions

2025–

Gynaecologist

AZ Groeninge · Department of Gynaecology and Obstetrics

2023–

Clinical Fellow

Universitaire Ziekenhuizen Leuven, KU Leuven · Department of Gynaecology and Obstetrics

2021–

Resident

Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven · Department of Gynaecology and Obstetrics

2020–

Resident

AZ Sint-Jan Brugge-Oostende AV · Department of Gynaecology and Obstetrics

2018–

Resident

AZ Delta · Department of Gynaecology and Obstetrics

Education

2023

Katholieke Universiteit Leuven · Residency Gynaecology & Obstetrics

2018

MD

KU Leuven

Country

BE

Keywords
MenopauseGynaecologyObstetrics